DLHCMEDIUM SIGNALOPERATIONAL10-K

DLHC experienced a dramatic operational turnaround with operating income surging 347% and gross profit up 262%, but declining net income suggests significant non-operating expenses offset these gains.

The company appears to be executing a strategic pivot away from cybersecurity services toward healthcare-focused data analytics and clinical research, evidenced by the removal of detailed cyber capability descriptions and emphasis on NIH/CDC partnerships. This operational restructuring, combined with reduced receivables and debt levels, suggests improved cash conversion but requires monitoring of the sustainability of these margin improvements.

Comparing 2025-12-10 vs 2024-12-04View on EDGAR →
FINANCIAL ANALYSIS

DLHC delivered exceptional operational performance with operating income jumping from $3.8M to $16.8M and gross profit increasing 262% to $30.2M, indicating significantly improved business efficiency and margin expansion. However, net income paradoxically fell 44% to $1.8M despite operational gains, suggesting substantial non-operating expenses or one-time charges absorbed the operational improvements. The balance sheet shows disciplined capital management with total debt declining 14.3% and current liabilities down 19.9%, though the 63% drop in cash to just $125K and 15% decline in operating cash flow warrant close attention to liquidity management.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+347%
$3.8M$16.8M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Gross Profit
P&L
+262.2%
$8.3M$30.2M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Cash & Equivalents
Balance Sheet
-63.5%
$342K$125K

Cash declined 63.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
-44.2%
$3.3M$1.8M

Net income declined 44.2% — review whether driven by operations, interest costs, or non-recurring items.

Accounts Receivable
Balance Sheet
-23%
$49.8M$38.4M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Current Liabilities
Balance Sheet
-19.9%
$53.2M$42.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
-19.7%
$53.0M$42.5M

Current assets declined 19.7% — monitor working capital adequacy and short-term liquidity.

Operating Cash Flow
Cash Flow
-15.2%
$27.4M$23.2M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Total Debt
Balance Sheet
-14.3%
$149.4M$128.0M

Debt reduced 14.3% — deleveraging strengthens balance sheet and reduces financial risk.

Total Liabilities
Balance Sheet
-13%
$204.2M$177.7M

Liabilities reduced 13% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2025-12-10
PRIOR — 2024-12-04
ADDED
As of December 9, 2025 there were 14,493,035 shares of the Registrant s common stock outstanding.
Our revenue is distributed to time and materials contracts (51.4%), firm fixed price contracts (27.2%) and cost reimbursable contracts (21.4%).
Our customers, including numerous institutes and centers within the National Institutes of Health ("NIH"), the Defense Health Agency ("DHA"), US Army Medical Research Development Command ("MRDC"), and US Navy, rely on our information technology support to enable their vital missions.
We primarily provide large-scale data analytics, testing and evaluation, clinical trials research services, and epidemiology studies to support multiple operating divisions within HHS, including NIH and the Center for Disease Control and Prevention ("CDC"), as well as the Military Health System.
This includes specialized engineering expertise, encompassing areas of Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance, and Reconnaissance ("C5ISR"), modeling, simulation training, performance based logistics, system modernization, technology-powered health solutions and software engineering on behalf of the US Navy, HHS, VA, and other federal customers.
+7 more — sign up free →
REMOVED
As of December 2, 2024 there were 14,386,468 shares of the Registrant s common stock outstanding.
Our revenue is distributed to time and materials contracts (54%), firm fixed price contracts (26%) and cost reimbursable contracts (20%).
Our customers, including numerous institutes and centers within the National Institutes of Health ("NIH"), the Defense Health Agency ("DHA"), Telemedicine and Advanced Technology Research Center ("TATRC"), and US Navy Naval Information Warfare Center ("NIWC"), rely on our information technology support to enable their vital missions.
We work with these customers to reduce risk and build resilience to cyber and physical threats to the federal government s infrastructure, providing the full spectrum of cyber capabilities, cryptographic and true cyber engineering, Certified Information Security Officer ("CISO") / Information System Security Officer ("ISSO") support, risk management frameworks, Continuity of Operations ("COOP") / Disaster Recovery, and enterprise infrastructure and cloud governance focused on designing and implementing zero trust architecture.
We primarily provide large-scale data analytics, testing and evaluation, clinical trials research services, and epidemiology studies to support multiple operating divisions within HHS, including NIH and the Center for Disease Control and Prevention ("CDC"), the Military Health System, and leading academic institutes.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →